jilipark download

NoneFRISCO, Texas (AP) — Dallas Cowboys linebacker DeMarvion Overshown could miss the 2025 season recovering from the right knee injury sustained in a loss to Cincinnati, coach Mike McCarthy said Tuesday. McCarthy said Overshown has a “long road of rehab in front of him.” The second-year player tore multiple ligaments when a Bengals lineman crashed into his leg in the Cowboys' 27-20 loss Monday night. Overshown missed all of his rookie year in 2023 after tearing the ACL in his left knee in a preseason game. The latest injury came in his first game since a spectacular 23-yard interception return for a touchdown in a 27-20 victory over the New York Giants on Thanksgiving. “DeMarvion is getting ready to have a big surgery in front of him,” McCarthy said of the procedure planned this week. “His physical and football talent speaks for itself. He’s such a bright light. He’s got a great, infectious personality — a tough young man. He is definitely going to be missed.” The former Texas standout, drafted in the third round last year, was second on the team to star pass rusher Micah Parsons with five sacks when he went down. The December timing of Overshown's injury means rehab is likely to extend past training camp and into the regular season next year, after he turns 25. Parsons was emotional when asked about Overshown after the Cincinnati game. “I cried,” he said. “It’s like my little bro, bro. He doesn’t deserve that either. Just to understand what he’s going to go through and to be there for him physically, mentally. It’s just so challenging because of the year he was having. I really just don’t think that’s fair either.” The loss of Overshown comes with defensive end DeMarcus Lawrence close to return from a foot injury that has sidelined him since Week 4. But the Cowboys (5-8) are all but out of the playoffs as they prepare to visit Carolina (3-10) on Sunday. AP NFL: https://apnews.com/hub/nfljilipark download 。

None

More than 20 states and cities designate December as Osteopathic Medicine MonthAsian Stocks Set for Sluggish Start as CPI Looms: Markets Wrap

Blue Square X Expands Art Curation Services at Art Basel MiamiHydrocodone IR is under clinical development by Elysium Therapeutics and currently in Phase I for Opium (Opioid) Addiction. According to GlobalData, Phase I drugs for Opium (Opioid) Addiction have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Hydrocodone IR overview Hydrocodone immediate release is under development for the treatment of pain due to prescription opioid use disorder and opium (Opioid) addiction. It acts by targeting mu-type opioid receptor. The drug candidate is developed based on O2P (oral overdose protection) technology. It is an immediate release formulation. It is administered through oral route. Elysium Therapeutics overview Elysium Therapeutics is developing safer opioids for the treatment of opioid use disorder. The company is headquartered in Lyons, Colorado, the US. For a complete picture of Hydrocodone IR’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .

None